Abstract:Acute myeloid leukemia (AML) is a high mortality and recurrence rates hematologic malignancy. Thus, whatever early detection or subsequent visit are both of high significance. Traditional AML diagnosis is conducted via peripheral blood (PB) smear and bone marrow (BM) aspiration. But BM aspiration is a painful burden for patients especially in early detection or subsequent visit. Herein, the use of PB to evaluate and identify the leukemia characteristics will be an attractive alternative source for early detection or subsequent visit. Fourier transform infrared spectroscopy (FTIR) is a time- and cost-effective approach to reveal the disease-related molecular features and variations. However, to the best of our knowledge, there is no attempts using infrared spectroscopic signatures of PB to replace BM for identifying AML. In this work, we are the first to develop a rapid and minimally invasive method to identify AML by infrared difference spectrum (IDS) of PB with only 6 characteristic wavenumbers. We dissect the leukemia-related spectroscopic signatures of three subtypes of leukemia cells (U937, HL-60, THP-1) by IDS, revealing biochemical molecular information about leukemia for the first time. Furthermore, the novel study links cellular features to complex features of blood system which demonstrates the sensitivity and specificity with IDS method. On this basis, BM and PB of AML patients and healthy controls were provided to parallel comparison. The IDS of BM and PB combined with principal component analysis method revealing that the leukemic components in BM and PB can be described by IDS peaks of PCA loadings, respectively. It is demonstrated that the leukemic IDS signatures of BM can be replaced by the leukemic IDS signatures of PB. In addition, the IDS signatures of leukemia cells are reflected in PB of AML patients with peaks of 1629, 1610, 1604, 1536, 1528 and 1404 cm −1 for the first time as well. To this end, we access the leukemic signatures of IDS peaks to compare the PB of AMLs and healthy controls. It is confirmed that the leukemic components can be detected from PB of AML and distinguished into positive (100%) and negative (100%) groups successfully by IDS classifier which is a novel and unique spectral classifier. This work demonstrates the potential use of IDS as a powerful tool to detect leukemia via PB which can release subjects' pain remarkably.

Monitoring All-Trans-Retinoic Acid-Induced Differentiation of HL-60 Cells by Fourier-Transform Infrared Spectroscopy

A Rapid Method for Detecting Conformational Changes During Differentiation and Apoptosis of HL60 Cells by Fourier‐transform Infrared Spectroscopy

Iron Metabolism in K562 Cell Differentiation Induced by ATRA

[Study on Matrine Alleviating Retinoic Acid Resistance in Acute Promyelocytic Leukemia].

Temporal Quantitative Proteomic and Phosphoproteomic Profiling of SH-SY5Y and IMR-32 Neuroblastoma Cells during All-Trans-Retinoic Acid-Induced Neuronal Differentiation

An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program

Application of selected reaction monitoring and parallel reaction monitoring for investigation of HL-60 cell line differentiation

A Clinical Study of All-Trans-retinoid-induced Differentiation Therapy of Advanced Thyroid Cancer

Cytoplasm Prepared from All-Trans Retinoic Acid (Atra)-Treated Human Hematopoietic Progenitor Cells Induces Differentiation of Both ATRA Sensitive and ATRA Resistant Leukemia Cells.

Evidence for identification of acute myeloid leukemia using peripheral blood's infrared spectrum and logistic regression

Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663

Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.

Identification of acute myeloid leukemia by infrared difference spectrum of peripheral blood

Comparative Proteomic Analysis of All-Trans-retinoic Acid Treatment Reveals Systematic Posttranscriptional Control Mechanisms in Acute Promyelocytic Leukemia

Differentiation-stimulating Potency of Differentiated HL60 Cells after Drug Treatment.

Data from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Fucosylation inhibitor 6-alkynylfucose enhances the ATRA-induced differentiation effect on acute promyelocytic leukemia cells

[Effects of All-Trans Retinoic Acid on Expression of Connexin Genes and Gap Junction Communication in Hepatocellular Carcinoma Cell Lines].

Regulatory Effect of All-Trans Retinoic Acid (atra) on the Activities of N-Acetylglucosaminyl Transferase (gnt) Iii, Iv in Hl-60 Cells

The HER2 Inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by Activating MEK/ERK Mediated RARα/STAT1 Axis

Alterations of specific chromatin conformation affect ATRA-induced leukemia cell differentiation